African American participation in prostate cancer clinical trials must move from 3-5% range to 10-12% range to determine the effectiveness of new treatments.
The U.S. Food and Drug Administration (FDA) approved apalutamide for the treatment of non-metastatic castration-resistant prostate cancer
Clinical trials have found that Enzalutamide and Apalutamide are both able to significantly delay prostate cancer progression in men with non-metastatic castration-resistant prostate cancer.
During a regular check-up in 2008, Ray Fuller was diagnosed with prostate cancer. There was no family history of the disease, he said, it “just popped up.”
New research demonstrates how the fat contained within the Western diet, in combination with genetic factors, can cause prostate cancer tumors to spread.
There is no good time to get such news, but it was particularly jarring when Robbie Robinson was diagnosed with prostate cancer in 2002.
FDA granted Priority Review to a New Drug Application for apalutamide according to a press release.